CA2722734C - 3,4-substituted piperidine derivatives as renin inhibitors - Google Patents

3,4-substituted piperidine derivatives as renin inhibitors Download PDF

Info

Publication number
CA2722734C
CA2722734C CA2722734A CA2722734A CA2722734C CA 2722734 C CA2722734 C CA 2722734C CA 2722734 A CA2722734 A CA 2722734A CA 2722734 A CA2722734 A CA 2722734A CA 2722734 C CA2722734 C CA 2722734C
Authority
CA
Canada
Prior art keywords
alkylene
halogens
optionally substituted
amine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2722734A
Other languages
English (en)
French (fr)
Other versions
CA2722734A1 (en
Inventor
Jeremy Peter Scott
Nadine Bremeyer
Austin Chih-Yu Chen
Daniel Dube
Pierre-Andre Fournier
Erich L. Grimm
Patrick Lacombe
Sebastien Laliberte
Dwight Macdonald
D. Bruce Mackay
Daniel James Mckay
Tom Yao-Hsiang Wu
Louis-Charles Campeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CA2722734A1 publication Critical patent/CA2722734A1/en
Application granted granted Critical
Publication of CA2722734C publication Critical patent/CA2722734C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA2722734A 2008-05-05 2009-05-04 3,4-substituted piperidine derivatives as renin inhibitors Expired - Fee Related CA2722734C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12652908P 2008-05-05 2008-05-05
US61/126,529 2008-05-05
US18830308P 2008-08-07 2008-08-07
US61/188,303 2008-08-07
PCT/CA2009/000611 WO2009135299A1 (en) 2008-05-05 2009-05-04 3, 4 - substituted piperidine derivatives as renin inhibitors

Publications (2)

Publication Number Publication Date
CA2722734A1 CA2722734A1 (en) 2009-11-12
CA2722734C true CA2722734C (en) 2013-11-05

Family

ID=41264366

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2722734A Expired - Fee Related CA2722734C (en) 2008-05-05 2009-05-04 3,4-substituted piperidine derivatives as renin inhibitors

Country Status (23)

Country Link
US (1) US8889714B2 (enExample)
EP (1) EP2274295B1 (enExample)
JP (3) JP4790871B2 (enExample)
KR (2) KR101403311B1 (enExample)
CN (1) CN102015682B (enExample)
AU (1) AU2009243875B2 (enExample)
BR (1) BRPI0912388A2 (enExample)
CA (1) CA2722734C (enExample)
CO (1) CO6311081A2 (enExample)
CR (1) CR11809A (enExample)
DO (1) DOP2010000329A (enExample)
EA (1) EA020853B1 (enExample)
ES (1) ES2548134T3 (enExample)
IL (1) IL208467A (enExample)
MA (1) MA32296B1 (enExample)
MX (1) MX2010012067A (enExample)
MY (1) MY152042A (enExample)
NI (1) NI201000188A (enExample)
NZ (1) NZ589019A (enExample)
PL (1) PL2274295T3 (enExample)
SG (1) SG192543A1 (enExample)
SV (1) SV2010003723A (enExample)
WO (1) WO2009135299A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2010066028A1 (en) * 2008-12-10 2010-06-17 Merck Frosst Canada Ltd. 3,4 - substituted piperidine derivatives as renin inhibitors
TWI622573B (zh) * 2010-11-05 2018-05-01 拜耳知識產權公司 藉由亞胺氫化製備經取代ｎ－（苄基）環丙胺之方法
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN107602381B (zh) * 2017-09-11 2021-03-16 陕西莱特光电材料股份有限公司 一种萘甲酸酯类衍生物及其制备方法
CN108033876A (zh) * 2017-12-20 2018-05-15 江汉大学 一种5-溴-2-氯苯甲醛的制备方法
EP3887357A1 (en) 2018-11-28 2021-10-06 Basf Se Pesticidal compounds
BR112022021631A2 (pt) 2020-04-28 2022-12-06 Basf Se Compostos, composição, métodos para combater ou controlar pragas invertebradas, para proteger plantas em crescimento e para tratar ou proteger um animal, semente e uso de um composto

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
KR100384979B1 (ko) 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
JP2001504457A (ja) 1996-11-01 2001-04-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) * 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
AU2003233963B2 (en) 2002-04-29 2008-09-11 Actelion Pharmaceuticals Ltd 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
BR0312000A (pt) 2002-06-27 2005-03-22 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
AU2004234040A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
BRPI0409881A (pt) 2003-04-29 2006-05-23 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
RU2005137174A (ru) 2003-04-30 2006-03-27 Актелион Фармасьютикалз Лтд. (Ch) Азабициклононеновые производные
WO2004096799A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd Tropane derivatives and their use as ace inhibitors
EP1622685A1 (en) 2003-04-30 2006-02-08 Actelion Pharmaceuticals Ltd. 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors
KR20060015573A (ko) 2003-05-02 2006-02-17 액테리온 파마슈티칼 리미티드 신규한 디아자비시클로노넨 유도체
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
WO2005040120A1 (en) 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Tetrahydropyridine derivatives
JP2007508262A (ja) 2003-10-13 2007-04-05 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネン誘導体およびその使用
JP2007509099A (ja) 2003-10-23 2007-04-12 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネンおよび新規極性側鎖を有するテトラヒドロピリジン誘導体
AU2004295092A1 (en) 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
WO2005054243A1 (en) 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
AR053406A1 (es) * 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
WO2006021399A2 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives as renin inhibitors
ATE462703T1 (de) 2004-08-25 2010-04-15 Actelion Pharmaceuticals Ltd Bicyclononen-derivate als renin-inhibitoren
WO2006021403A1 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicyclononene derivatives
WO2006021401A2 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicylononene derivatives
WO2006058546A1 (en) 2004-12-01 2006-06-08 Actelion Pharmaceuticals Ltd Novel lactame derivatives as renin inhibitors
AR052263A1 (es) 2004-12-08 2007-03-07 Actelion Pharmaceuticals Ltd Derivado de diazabiciclononeno
WO2006063610A1 (en) 2004-12-17 2006-06-22 Actelion Pharmaceuticals Ltd Heteroaryl substituted diazabicyclononene derivatives
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
ATE514697T1 (de) 2005-01-28 2011-07-15 Actelion Pharmaceuticals Ltd 7-ä4-ä2-(2,6-dichloro-4- methylphenoxy)ethoxyüphenylü-3,9- diazabicycloä3.3.1ünon-6-ene-6-carbonsäure- cyclopropyl-(2,3-dimethylbenzyl)amid als renin- hemmer für die behandlung von bluthochdruck
WO2006092268A1 (en) 2005-03-02 2006-09-08 Actelion Pharmaceuticals Ltd Bicyclic five-membered heteroaryl derivatives and their use as renin inhibitors
GB0504850D0 (en) * 2005-03-09 2005-04-13 Novartis Ag Organic compounds
EP1863763A1 (en) 2005-03-31 2007-12-12 Speedel Experimenta AG 3,4,5-substituted piperidines as renin inhibitors
TW200716622A (en) 2005-03-31 2007-05-01 Speedel Experimenta Ag Substituted piperidines
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
BRPI0609890A2 (pt) 2005-05-27 2010-05-04 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2006131884A2 (en) 2005-06-07 2006-12-14 Actelion Pharmaceuticals Ltd Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors
CA2615048A1 (en) 2005-07-22 2007-01-25 Merck Frosst Canada Ltd. Renin inhibitors
WO2007034406A1 (en) 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
WO2007034445A2 (en) 2005-09-26 2007-03-29 Actelion Pharmaceuticals Ltd Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency
WO2007049224A1 (en) 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
PT2420491E (pt) 2005-12-30 2013-10-14 Novartis Ag Compostos de piperidina 3,5-substituída como inibidores de renina
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
RU2425032C2 (ru) 2006-02-02 2011-07-27 Актелион Фармасьютикалз Лтд Вторичные амины в качестве ингибиторов ренина
BRPI0708487A2 (pt) 2006-03-03 2011-05-31 Actelion Pharmaceuticals Ltd composto, composição farmacêutica que o compreende e seu uso
CL2007000595A1 (es) 2006-03-08 2008-01-04 Actelion Pharmaceuticals Ltd Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EP2081927B1 (en) 2006-09-18 2011-08-17 Vitae Pharmaceuticals, Inc. Piperidine derivatives as renin inhibitors
DE602007007664D1 (de) * 2006-11-17 2010-08-19 Merck Frosst Canada Inc Renininhibitoren
US8343968B2 (en) * 2007-05-24 2013-01-01 Merck Canada Inc. Case of renin inhibitors
US20110207783A1 (en) 2007-08-07 2011-08-25 Daniel Dube Renin inhibitors
CA2707565A1 (en) * 2007-12-04 2009-06-11 Merck Frosst Canada Ltd. Renin inhibitors
JP2011520924A (ja) 2008-05-22 2011-07-21 メルク フロスト カナダ リミテツド レニン阻害剤としての３，４−置換ピペリジン誘導体
WO2011020193A1 (en) 2009-08-18 2011-02-24 Merck Frosst Canada Ltd. Renin inhibitors

Also Published As

Publication number Publication date
PL2274295T3 (pl) 2016-01-29
IL208467A (en) 2014-07-31
CN102015682B (zh) 2014-07-16
JP5587246B2 (ja) 2014-09-10
AU2009243875B2 (en) 2011-12-01
NZ589019A (en) 2012-10-26
IL208467A0 (en) 2010-12-30
EP2274295B1 (en) 2015-08-05
CA2722734A1 (en) 2009-11-12
SV2010003723A (es) 2011-01-24
JP2011225579A (ja) 2011-11-10
JP2011519871A (ja) 2011-07-14
DOP2010000329A (es) 2011-01-15
CN102015682A (zh) 2011-04-13
KR20130029116A (ko) 2013-03-21
MY152042A (en) 2014-08-15
ES2548134T3 (es) 2015-10-14
JP5653842B2 (ja) 2015-01-14
KR20100131007A (ko) 2010-12-14
BRPI0912388A2 (pt) 2017-09-26
AU2009243875A1 (en) 2009-11-12
JP2011225580A (ja) 2011-11-10
MX2010012067A (es) 2010-12-06
CO6311081A2 (es) 2011-08-22
US8889714B2 (en) 2014-11-18
SG192543A1 (en) 2013-08-30
NI201000188A (es) 2012-02-02
WO2009135299A1 (en) 2009-11-12
KR101403311B1 (ko) 2014-06-05
EP2274295A4 (en) 2012-03-28
MA32296B1 (fr) 2011-05-02
EA201071269A1 (ru) 2011-06-30
EA020853B1 (ru) 2015-02-27
EP2274295A1 (en) 2011-01-19
JP4790871B2 (ja) 2011-10-12
CR11809A (es) 2011-01-10
US20110053940A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
CA2722734C (en) 3,4-substituted piperidine derivatives as renin inhibitors
US10906890B2 (en) Triazole phenyl compounds as agonists of the APJ receptor
CA3022561A1 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
CZ2001850A3 (cs) Deriváty 4,4-biarylpiperidinu s účinností na opioidní receptor
JP2011519858A (ja) プロリルヒドロキシラ−ゼ阻害剤
US20110152316A1 (en) 3,4-substituted piperidine derivatives as renin inhibitors
CA2756780A1 (en) Renin inhibitors
CN114340616A (zh) 作为食欲肽拮抗剂的吡唑和咪唑衍生物、组合物以及方法
CA2555800C (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
AU2009326797B2 (en) 3,4 - substituted piperidine derivatives as renin inhibitors
TW202304864A (zh) 1,3-取代的環丁基衍生物及其用途
TWI472524B (zh) 腎素抑制劑
BR122025005591B1 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831